オキシフェドリンは,アンチアンギナル剤として用いられる.

Degradation of bradykinin, a cardioprotective substance, during a single passage through isolated rat-heart.

Archives of pharmacal research·2006

Atrial natriuretic peptide reduces the severe consequences of coronary artery occlusion in anaesthetized dogs.

Cardiovascular drugs and therapy·2000

Isosorbide-2-mononitrate reduces the consequences of myocardial ischaemia, including arrhythmia severity: implications for preconditioning.

Cardiovascular drugs and therapy·2000

The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin.

British journal of pharmacology·2000

Coronary vascular endothelium-myocyte interactions in protection of the heart by ischaemic preconditioning.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2000

Delayed protection against ventricular arrhythmias by monophosphoryl lipid-A in a canine model of ischaemia and reperfusion.

European journal of pharmacology·1999

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Olfactomedin 2 Promotes Atherosclerosis by Eliciting Smooth Muscle Foam Cell Formation.

Arteriosclerosis, thrombosis, and vascular biology·2026

Neutral-cumulenic diazo (X[double bond, length as m-dash]C[double bond, length as m-dash]N2) compounds.

Chemical science·2026

Asymmetric radical type 1,2-aryloxy-phosphinolylation of vinylarenes catalyzed by chiral vanadyl complexes.

Communications chemistry·2026

A Postsynthetic Strategy for Oligonucleotides Containing 2-Fluoro-adenine and Isoguanine Nucleobases.

Organic letters·2026

NO and NO2 reactions with oxygenated peroxy radicals lead to indistinguishable product compositions: computational insights from cyclohexene oxidation in presence of NO x.

Environmental science: atmospheres·2026

Formation of Hydroxylated-Benzoyl-Benzofuranones Following the Exposure of Quercetin and Kaempferol to aNitrite-Containing Acidic Medium.

Molecules (Basel, Switzerland)·2026

関連する実験動画

オキシフェドリンは,アンチアンギナル剤として用いられる.

関連する概念動画

Degradation of bradykinin, a cardioprotective substance, during a single passage through isolated rat-heart.

Atrial natriuretic peptide reduces the severe consequences of coronary artery occlusion in anaesthetized dogs.

Isosorbide-2-mononitrate reduces the consequences of myocardial ischaemia, including arrhythmia severity: implications for preconditioning.

The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin.

Coronary vascular endothelium-myocyte interactions in protection of the heart by ischaemic preconditioning.

Delayed protection against ventricular arrhythmias by monophosphoryl lipid-A in a canine model of ischaemia and reperfusion.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Olfactomedin 2 Promotes Atherosclerosis by Eliciting Smooth Muscle Foam Cell Formation.

Neutral-cumulenic diazo (X[double bond, length as m-dash]C[double bond, length as m-dash]N<sub>2</sub>) compounds.

Asymmetric radical type 1,2-aryloxy-phosphinolylation of vinylarenes catalyzed by chiral vanadyl complexes.

A Postsynthetic Strategy for Oligonucleotides Containing 2-Fluoro-adenine and Isoguanine Nucleobases.

NO and NO<sub>2</sub> reactions with oxygenated peroxy radicals lead to indistinguishable product compositions: computational insights from cyclohexene oxidation in presence of NO <sub><i>x</i></sub>.

Formation of Hydroxylated-Benzoyl-Benzofuranones Following the Exposure of Quercetin and Kaempferol to aNitrite-Containing Acidic Medium.

関連する実験動画

オキシフェドリンは,アンチアンギナル剤として用いられる.

関連する概念動画

関連記事